Pazopanib Is More Cost-Effective Than Sunitinib for Treatment of mRCC in Canada
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cost-Effectiveness of Pazopanib Compared With Sunitinib in Metastatic Renal Cell Carcinoma in Canada
Curr Oncol 2016 Aug 01;23(4)e340-e354, J Amdahl, J Diaz, J Park, HR Nakhaipour, TE DeleaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.